Financial health
- Operating income covered interest expense -507.5× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2026 | — | -$7M | — | — | -$7M | — | $5M |
| 2025 | — | -$13M | — | — | -$8M | — | $6M |
| 2024 | $0 | -$12M | — | — | -$10M | — | $5M |
| 2023 | $574245 | -$12M | 0.0% | -2072.0% | -$11M | — | $15M |
| 2022 | $294165 | -$10M | 0.0% | -3542.5% | -$10M | — | $17M |
| 2021 | $659104 | -$8M | 0.0% | -1197.3% | -$7M | — | $10M |
| 2020 | $650187 | -$6M | 0.0% | -912.0% | -$5M | — | $10M |
| 2019 | $229625 | -$6M | 0.0% | -2612.5% | -$4M | — | — |
| 2018 | — | -$6M | — | — | -$4M | — | — |
| 2017 | — | -$7M | — | — | -$4M | — | — |
| 2016 | — | -$5M | — | — | -$4M | — | — |
| 2015 | — | -$7M | — | — | -$5M | — | — |
| 2014 | — | -$13M | — | — | -$2M | — | — |
| 2013 | — | -$5M | — | — | -$2M | — | — |
| 2012 | — | -$8M | — | — | -$2M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$2M | — | — | — | — | $5M |
| Dec '25 | — | -$2M | — | — | — | — | $7M |
| Sep '25 | — | -$1M | — | — | — | — | $6M |
| Jun '25 | — | -$2M | — | — | — | — | $4M |
| Mar '25 | — | -$6M | — | — | -$2M | — | $6M |
| Dec '24 | — | -$2M | — | — | -$2M | — | $5M |
| Sep '24 | — | -$3M | — | — | -$2M | — | $7M |
| Jun '24 | — | -$3M | — | — | -$2M | — | $9M |
| Mar '24 | — | -$2M | — | — | -$3M | — | $5M |
| Dec '23 | — | -$3M | — | — | -$2M | — | $8M |
| Sep '23 | — | -$3M | — | — | -$3M | — | $10M |
| Jun '23 | — | -$3M | — | — | -$3M | — | $13M |
| Mar '23 | $574245 | -$2M | 0.0% | -431.5% | -$3M | — | $15M |
| Dec '22 | $0 | -$3M | — | — | -$2M | — | $17M |
| Sep '22 | $0 | -$4M | — | — | — | — | $20M |
| Jun '22 | $0 | -$3M | — | — | -$3M | — | $15M |
| Mar '22 | $13116 | -$4M | 0.0% | -28863.2% | -$3M | — | $17M |
| Dec '21 | $17117 | -$3M | 0.0% | -14768.6% | -$3M | — | $20M |
| Sep '21 | $131966 | -$2M | 0.0% | -1522.2% | — | — | $23M |
| Jun '21 | $131966 | -$2M | 0.0% | -1590.1% | -$2M | — | $25M |
How the market has priced AEMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for AETHLON MEDICAL INC's multi-year trend.
As of FY2026, AETHLON MEDICAL INC reported — of total debt against $5M of cash; operating income covered interest expense -507.5×.
In FY2026, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.